Oppenheimer Reiterates 'Outperform' Rating on Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is considered one of the top 10 defensive stocks in a volatile market. Oppenheimer reiterated an ‘Outperform’ rating on July 3 with a $14 price target following the Centers for Medicare & Medicaid Services’ decision on transcatheter edge-to-edge repair for the tricuspid valve (T-TEER).

The recent decision eliminates certain requirements for specialists and patient consultations, benefiting tricuspid valve (T-TEER) procedures. Despite conflicting opinions on volume standards, CMS did not enforce specific requirements, providing flexibility for optimal medical therapy in line with FDA labeling.

Abbott Laboratories is a healthcare company specializing in a range of healthcare products, including generic pharmaceuticals and laboratory systems. While ABT is a solid investment, some analysts believe certain AI stocks offer greater potential upside and lower risk.

For more information on materials and organic food stocks, visit Insider Monkey. No disclosures in this article.

Read more at Yahoo Finance: Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT)